Lowenstein Sandler represented Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a precision oncology company with a diversified portfolio, in the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
All of the common stock was sold at a public offering price of $19.00 per share for a total public offering size of approximately $94.5 million, before deducting underwriting discounts and offering expenses.
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
The Lowenstein deal team included Michael J. Lerner, Steven M. Skolnick, Stephen Zapf, and Donna Calia.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.
